The response deadline has passed. Review the details for future reference or to track similar opportunities.
The Department of Defense, through the Defense Health Agency, is procuring pharmaceutical agents for inclusion in the Military Health System’s Uniform Formulary via Blanket Purchase Agreements and Additional Discount Programs, requiring industry quotes based on clinical and cost-effectiveness evaluations for four newly approved drugs: Lifyorli, Quiofic, Widaplik, and Saphnelo.
The Defense Health Agency is evaluating pharmaceutical agents for inclusion in the DoD Uniform Formulary based on clinical and cost-effectiveness criteria, with the goal of establishing Blanket Purchase Agreements and Additional Discount Programs for selected drugs.
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed: a. Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist b. Quiofic - VITAMINS - WATER SOLUBLE c. Widaplik - ANTIHYPERTENSIVE AGENTS – N/A d. Saphnelo – IMMUNOSUPPRESSIVES – N/A The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9302. Pre-quotation teleconference is on May 13, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical
questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. Tracy Banks Alternative
Point of Contact Kirk Heyen .931.766 Contracting , BAY D, TX 78234 USA to this opportunity. A-3 RFQ HT9402-26-Q-9302.pdf A-3 Price List - Widaplik - Antihypertensive Agents-NA.xlsx A-3 Price List - Lifyorli - Oncological Agents - Glucocorticoid Receptor Antagonist.xlsx A-3 Price List - Saphnelo - Immunosuppressives - NA.xlsx A-3 Price List - Quiofic - Vitamins - Water Soluble.xlsx A-3 Price Appendix FAQ NAD.pdf
Get matched to contracts like this daily
Free AI-powered contract matching for your business.